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Abstract
Background: The incidence of anal squamous cell carcinoma (SCC) has been steadily growing globally in the past
decade. Clinical data on anal SCC from China are rare. We conducted this study to describe the clinical and
epidemiological characteristics of anal SCC in China and explore prognostic factors of outcomes among patients
with anal SCC.
Methods: We audited demographic characteristics, relevant symptoms, risk factors, treatment modalities and outcomes
for patients diagnosed with anal SCC at 11 medical institutions in China between January 2007 and July 2018.
Results: A total of 144 patients (109 females) were diagnosed with SCC during this period. Median age at initial diagnosis
was 52.0 (interquartile range: 46.0–61.8) years. The most common symptoms were bleeding (n = 93, 64.6%), noticing a
lump (n = 49, 34.0%), and pain (n = 47, 32.6%). The proportion of patients at the American Joint Committee on Cancer
(AJCC) stages I-IV were 10 (6.9%), 22 (15.3%), 61 (42.4%) and 8 (5.6%), respectively, and AJCC stages in 43 (29.9%) patients
were unknown. Thirty-six patients (25.0%) underwent abdominoperineal resection initially. Univariable analysis showed
that T stage predicted recurrence-free survival (RFS) (Hazard ratio [HR] = 3.03, 95% Confidence interval [CI]: 1.10–8.37, p =
0.032), and age group (HR = 2.90, 95% CI: 1.12–7.49, p = 0.028), AJCC stage (HR = 4.56, 95% CI: 1.02–20.35, p = 0.046), and N
stage (HR = 3.05, 95% CI: 1.07–8.74, p = 0.038) predicted overall survival (OS).
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Conclusions: T stage was identified as prognostic factor of RFS, and age, AJCC stage, and N stage were identified as
prognostic factors of OS. Improving symptom awareness and earlier presentation among patients potentially at risk for
anal SCC should be encouraged. Familiarity with the standard treatment among health care providers in China should be
further improved.
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Background
Anal cancer is a malignancy accounting for 1–2% of di-
gestive tract tumours and 2–4% of colorectal and anal
tumours [1–3]. In the general population, anal cancer is
rare with an overall incidence rate between 1 and 2/100,
000 person-years [4]. It arises from the squamous epi-
thelium of the anal canal and/or perianal skin. Anal can-
cer can be divided histologically into different subtypes:
squamous cell carcinomas (SCC), adenocarcinoma,
adeno-squamous carcinoma and melanoma [5, 6]. In
Western countries, SCC is much more common than
adenocarcinoma. The incidence rate of SCC is steadily
increasing throughout the world including in the United
States, UK and Australia [7–11]. The main etiological
agent for anal SCC is high-risk human papillomavirus
(HPV) and hence anal receptive intercourse. HPV-
related vulvar or cervical cancer/dysplasia, Human Im-
munodeficiency Virus (HIV), history of transplantation/
chronic immunosuppression all increase its risk [9]. Pre-
vious studies also mentioned that the use of tobacco sig-
nificantly increased the risk of anal SCC [12, 13]. Men
who have sex with men (MSM) living with HIV have the
highest risk of anal SCC, with an incidence rate of 78/
100,000 person-years [14].
Before mid-1980s, the standard treatment for SCC was
abdominoperineal resection (APR), however because of
several disadvantages, such as permanent stoma, this
method as first line therapy was abandoned [3]. In 1974,
Nigro introduced combined chemoradiotherapy (CRT)
for the treatment of anal SCC [15], which was accepted
as a standard treatment after several clinical trials
proved its advantages, such as higher local control rates
and better organ preservation [16–18]. Surgery is often
used for salvage treatment in patients whose local le-
sions do not respond to treatment and can also be used
as primary treatment option when tumours arise from
anal margin and be diagnosed at stage I [3].
One of the key factors that influence the outcomes of
anal SCC is the stage at diagnosis [19, 20]. A study in
the United States indicated that the 5-year survival in
patients with a tumour size of ≤2 cm was 85%, but in pa-
tients with a tumour size of > 5 cm it was only 45% [21].
The findings from studies in France, Norway and
Australia were similar [22, 23]. A study in Norway men-
tioned that male gender and advanced T-stage could
increase the risk of recurrence and death of anal SCC
patients [24]. A study in the United States revealed that
advanced T stage and immune marker e.g. tumour indo-
leamine 2,3 dioxygenase 1 (IDO 1) could be used as pre-
dictor of recurrence [25].
It is not clear whether the findings from studies car-
ried out in Europe or North America are generalizable
to China where literature on anal SCC is scarce. We
conducted this study to understand the clinical and epi-
demiological characteristics of anal SCC and prognostic
factors of outcomes in patients with anal SCC in China.
Methods
We audited anal SCC patients recorded in 11 medical
institutions in China between January 2007 and July
2018. (Affiliated Cancer Hospital & institute of
Guangzhou Medical University, Guangzhou Panyu Cen-
tral Hospital, The First Affiliated Hospital of Sun Yat-
sen University, Sun Yat-sen Memorial Hospital, The
Third Affiliated Hospital of Sun Yat-sen University, The
Sixth Affiliated Hospital of Sun Yat-sen University
(Guangdong Gastrointestinal Hospital), Sun Yat-sen
University Cancer Center, The Second Affiliated Hos-
pital of Zhejiang University, Union Hospital, Tongji
Medical College, Huazhong University of Science and
Technology, Nanfang Hospital, Southern Medical Uni-
versity, Guangdong General Hospital). Patients with anal
SCC were identified using the International Classifica-
tion of Disease (ICD)-10 codes of anal SCC (C 21.0–
21.8) [26]. Adenocarcinomas were excluded. In order to
understand the patients’ outcomes more clearly, we con-
ducted a follow-up audit in May 2020 to all patients.
For all identified patients, medical records were
reviewed by author PY Li for demographic information
(e.g. age of diagnosis, gender, marital status), relevant
symptoms (e.g. bleeding, pain, tenesmus, noticing a
lump, perianal itch, altered bowel habit or obstruction,
etc.), risk factors (e.g. smoking behavior, history of anal
sex, history of cancer, HIV status), information of the
tumour (e.g. location, histology, tumour size, TNM
stage, American Joint Committee on Cancer [AJCC]
stage), treatment received (e.g. chemotherapy, radiother-
apy, CRT, surgery) and outcomes. AJCC stage was deter-
mined according to the American Joint Committee on
Cancer, 7th edition [27].
Lu et al. BMC Cancer          (2020) 20:679 Page 2 of 13
Data obtained from the medical records were summa-
rized using descriptive statistical analysis. Frequencies
and percentages were used to describe categorical vari-
ables and median and interquartile range (IQR) were
used to describe continuous variables. Chi-square test
was used to compare proportion of categorical variables.
For analysis, age was divided into two groups: ≤50 years
and >50 years. Tumour size was divided into two groups:
≤20mm and >20mm. Recurrence-free survival (RFS)
was defined as the interval between diagnosis and recur-
rence (local or distant). Overall survival (OS) was de-
fined as the interval between diagnosis and death from
any cause or last follow-up [6, 28, 29]. At the last follow-
up, patients who did not present an event of interest
were censored. Kaplan-Meier analyses were used to
evaluate RFS and OS. Cox proportional hazards regres-
sion analysis was performed to identify significant prog-
nostic factors of OS and RFS. All statistical analyses
were done using SPSS 20.0. A p value less than 0.05 was
considered to be statistically significant.
This study was approved by the Ethics Committee of
the University of New South Wales (IRB ID: HC180393)
and the Ethics Committee of the School of Public
Health, Sun Yat-sen University (IRB ID: 2018–026). Be-
cause the study was retrospective and the data was de-
identified, the informed consent requirement was
waived.
Results
A total of 144 patients were identified with anal SCC di-
agnosed between January 2007 and July 2018 (Table 1).
Most (87.5%) patients were diagnosed after 2010.
Among these patients, 109 (75.7%) were female. The
median age at initial diagnosis was 52.0 (IQR: 46.0–61.8)
years (Table 2). 91.4 and 95.4% of male and female pa-
tients were married (p = 0.637). When grouped by age at
initial diagnosis, 41.7% of patients (n = 60) were less than
or equal to 50 years, and 58.3% of patients (n = 84) were
older than 50 years.
Only one (0.7%) patient (male, 45 years old) was re-
corded as HIV positive. Four (2.8%) patients had a his-
tory of other cancers (two cervical cancers and two
vulvar cancers). Two (1.4%) patients were diagnosed
with sexually transmitted diseases (one syphilis, one had
anal intraepithelial neoplasia (AIN) 3 with syphilis and
genital warts) while being diagnosed with anal cancer.
One (0.7%) patient had a history of genital warts. Among
113 (78.5%) patients with a record of their sexual behav-
iors, no one reported a history of receptive anal inter-
course or homosexual behavior. Seventeen (11.8%)
patients were smokers (including current smokers and
ex-smokers).
Median duration of symptoms until initial diagnosis
was 90 days (IQR: 30–180 days). The most common
symptoms were bleeding (n = 93, 64.6%), noticing a lump
(n = 49, 34.0%), pain (n = 47, 32.6%), altered bowel habit
(n = 32, 22.2%), perianal itch (n = 22, 15.3%), and tenes-
mus (n = 20, 13.9%). Other symptoms (e.g. constipation
[n = 2], diarrhea [n = 4], thinner feces [n = 4], feces with
mucus [n = 4], and inguinal mass [n = 3]) also have been
observed. One patient who was diagnosed by physical
examination reported no symptom.
The median tumour size was 30.0 (IQR: 20.0–40.5)
mm. About one in four patients (n = 35, 24.3%) had
a tumour less than or equal to 20.0 mm. There were
13 (9.0%) patients diagnosed at T 1 stage, 40
(27.8%), 28 (19.4%), and 36 (25.0%) at stages T 2–4,
respectively. The frequencies and proportion of pa-
tients in N0–3 stages were 52 (36.1%), 33 (22.9%),
22 (15.3%) and 8 (5.6%), respectively. The frequen-
cies and proportion of patients in AJCC stages I-IV
were 10 (6.9%), 22 (15.3%), 61 (42.4%) and 8 (5.6%),
respectively, and AJCC stages in 43 (29.9%) patients
were unknown.
Table 1 Number of patients from participating medical institutions
Medical institution City Number of patients
Sun Yat-sen University Cancer Center Guangzhou 46
The Sixth Affiliated Hospital of Sun Yat-sen University (Guangdong Gastrointestinal Hospital) Guangzhou 28
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 19
The First Affiliated Hospital of Sun Yat-sen University Guangzhou 14
Nanfang Hospital, Southern Medical University Guangzhou 11
Affiliated Cancer Hospital & institute of Guangzhou Medical University Guangzhou 9
The Second Affiliated Hospital of Zhejiang University Hangzhou 6
Sun Yat-sen Memorial Hospital Guangzhou 5
Guangzhou Panyu Central Hospital Guangzhou 3
Guangdong General Hospital Guangzhou 2
The Third Affiliated Hospital of Sun Yat-sen University Guangzhou 1
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Table 2 Characteristics of patients, tumour and treatment modalities by gendera
Variable All patient (N = 144)
n (%)
Females (N = 109)
n (%)
Males (N = 35)
n (%)
Part 1 Demographics
Age (Median, IQR) 52.0 (46.0–61.8) 51.0 (45.5–58.0) 60.0 (51.0–72.0)
Age (Range) 17–86 27–84 17–86
Marital status
Married 136 (94.4%) 104 (95.4%) 32 (91.4%)
Single 2 (1.4%) 1 (0.9%) 1 (2.9%)
Divorced 4 (2.8%) 3 (2.8%) 1 (2.9%)
Widowed 1 (0.7%) 0 (0%) 1 (2.9%)
Unknown 1 (0.7%) 1 (0.9%) 0 (0%)
Part 2 History of other diseases and symptoms
History of smoking
Yes 17 (11.8%) 3 (2.8%) 14 (40.0%)
No 113 (78.5%) 96 (88.1%) 17 (48.6%)
Unknown 14 (9.7%) 10 (9.2%) 4 (11.4%)
History of cervical cancer
Yes – 2 (1.8%) –
No – 89 (81.7%) –
Unknown – 18 (16.5%) –
History of vulvar cancer
Yes – 2 (1.8%) –
No – 89 (81.7%) –
Unknown – 18 (16.5%) –
History of receptive anal intercourse or homosexual behavior
Yes 0 (0%) 0 (0%) 0 (0%)
No 113 (78.5%) 88 (80.7%) 25 (71.4%)
Unknown 31 (21.5%) 21 (19.3%) 10 (28.6%)
HIV status
Positive 1 (0.7%) 0 (0%) 1 (2.9%)
Negative 120 (83.3%) 91 (83.5%) 29 (82.9%)
Unknown 23 (16.0%) 18 (16.5%) 5 (14.3%)
Altered bowel habit
Yes 32 (22.2%) 24 (22.0%) 8 (22.9%)
No 112 (77.8%) 85 (78.0%) 27 (77.1%)
Bleeding
Yes 93 (64.6%) 75 (68.8%) 18 (51.4%)
No 51 (35.4%) 34 (31.2%) 17 (48.6%)
Pain
Yes 47 (32.6%) 32 (29.4%) 15 (42.9%)
No 97 (67.4%) 77 (70.6%) 20 (57.1%)
Noticing a lump
Yes 49 (34.0%) 35 (32.1%) 14 (40.0%)
No 95 (66.0%) 74 (67.9%) 21 (60.0%)
Perianal itch
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Table 2 Characteristics of patients, tumour and treatment modalities by gendera (Continued)
Variable All patient (N = 144)
n (%)
Females (N = 109)
n (%)
Males (N = 35)
n (%)
Yes 22 (15.3%) 17 (15.6%) 5 (14.3%)
No 122 (84.7%) 92 (84.4%) 30 (85.7%)
Tenesmus
Yes 20 (13.9%) 14 (12.8%) 6 (17.1%)
No 124 (86.1%) 95 (87.2%) 29 (82.9%)
Part 3 Characteristics of tumour
Tumor site
Anal margin 14 (9.7%) 8 (7.3%) 6 (17.1%)
Anal canal 119 (82.6%) 95 (87.2%) 24 (68.6%)
Both 5 (3.5%) 3 (2.8%) 2 (5.7%)
Unknown 6 (4.2%) 3 (2.8%) 3 (8.6%)
Tumor size
≤ 20 mm 35 (24.3%) 30 (27.5%) 5 (14.3%)
> 20mm 72 (50.0%) 55 (50.5%) 17 (48.6%)
Unknown 37 (25.7%) 24 (22.0%) 13 (37.1%)
T stage
T1 13 (9.0%) 12 (11.0%) 1 (2.9%)
T2 40 (27.8%) 29 (26.6%) 11 (31.4%)
T3 28 (19.4%) 24 (22.0%) 4 (11.4%)
T4 36 (25.0%) 27 (24.8%) 9 (25.7%)
Unknown 27 (18.8%) 17 (15.6%) 10 (28.6%)
N stage
N0 52 (36.1%) 42 (38.5%) 10 (28.6%)
N1 33 (22.9%) 25 (22.9%) 8 (22.9%)
N2 22 (15.3%) 16 (14.7%) 6 (17.1%)
N3 8 (5.6%) 7 (6.4%) 1 (2.9%)
Unknown 29 (20.1%) 19 (17.4%) 10 (28.6%)
M stage
M0 110 (76.4%) 87 (79.8%) 23 (65.7%)
M1 7 (4.9) 5 (4.6%) 2 (5.7%)
Unknown 27 (18.8) 17 (15.6%) 10 (28.6%)
AJCC stage
I 10 (6.9%) 9 (8.3%) 1 (2.9%)
II 22 (15.3%) 17 (15.6%) 5 (14.3%)
III 61 (42.4%) 48 (44.0%) 13 (37.1%)
IV 8 (5.6%) 6 (5.5%) 2 (5.7%)
Unknown 43 (29.9%) 29 (26.6%) 14 (40.0%)
Part 4 SCC treatment
Chemotherapy
Yes 107 (74.3%) 82 (75.2%) 25 (71.4%)
No 30 (20.8%) 21 (19.3%) 9 (25.7%)
Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
Radiotherapy
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As for diagnosis and treatment modalities, two pa-
tients were misdiagnosed with haemorrhoids and under-
went haemorrhoidectomy. Chemotherapy was
administered to 74.3% (n = 107) of patients, and radio-
therapy to 70.1% (n = 101) of patients. Ninety-seven
(67.4%) patients underwent CRT. Thirty-six patients
(25.0%) underwent APR initially, of which four, five,
eight, and zero patients were in AJCC stage I, II, III, and
IV, respectively, and AJCC stages of the remaining pa-
tients were unknown. Of the 36 patients who underwent
surgery initially, 24 patients had performed only APR,
and eight, three, and one patient had performed CRT,
chemotherapy, and radiotherapy after APR, respectively.
Tumour sites treated with APR were anal canal or anal
canal and margin. Fifteen (10.4%) patients were treated
with local mass resection. Only two patients underwent
local mass resection were diagnosed at stage I, and sites
of tumour were anal margin.
In the current study, seven patients were diagnosed at
M1 stage. The metastatic sites were liver in three patients,
lung in one patient, sigmoid colon, vagina, uterus, bladder,
pelvic, and retroperitoneal lymph nodes in one patient,
and left supraclavicular, vena cava and para-aortic lymph
nodes in one patient. As for treatment, two patients re-
ceived induction chemotherapy plus concurrent chemora-
diotherapy followed by adjuvant chemotherapy, two
patients underwent induction chemotherapy plus concur-
rent chemoradiotherapy, two patients received chemo-
therapy alone, and one patient did not receive any
treatment. The mainstream chemotherapy regimen was
docetaxel plus cisplatin (TP), other regiments, such as
fluorouracil plus cisplatin (PF), FOLFOX and Capox were
also involved. Among the patients diagnosed at M1 stage,
the radiation dose varied from 5400 cGy to 6000 cGy, and
the frequency of radiotherapy varied 25 to 30 times. Volu-
metric intensity modulated arc therapy (VMAT) and
intensity modulated radiotherapy (IMRT) were the most
often adopted technique. Among these patients, five died
of cancer, one survived, and one lost to follow-up.
The chemotherapy regimens were not uniform and
varied across different medical institutions. Among all
the 144 patients, TP, PF and fluorouracil (5-FU) plus mi-
tomycin were the most widely used. FOLFOX, Capox,
capecitabine monotherapy, 5-FU monotherapy, and cis-
platin monotherapy were also used in some hospitals.
Concurrent chemotherapy was applied to more than half
of the patients, and the others were treated with induc-
tion chemotherapy, adjuvant chemotherapy or both. For
radiotherapy, apart from some earlier patients who
adopted 3-dimensional conformal radiation therapy (3D-
CRT), the rest patients all adopted VMAT or IMRT
technique. Radiation dose had a wide range, fluctuating
between 3780 cGy and 7000 cGy. The median of radi-
ation dose was 5600 cGy (IQR: 5000–6000 cGy). The fre-
quency of radiotherapy varied from 21 to 35. Every
single dose, with maximum at 240 cGy and minimum at
180 cGy, was performed five times per week.
Within a median follow-up of 44months (IQR: 25–67
months), 22 patients died of anal SCC and 25 patients devel-
oped a recurrence. Estimated 5-year RFS was 79.4%, and 5-
year OS was 82.8%. The univariable analysis of RFS showed
that T stage was a significant prognostic factor of RFS (Haz-
ard ratio [HR] = 3.03, 95% Confidence interval [CI]: 1.10–
8.37, p= 0.032; Table 3; Fig. 1). The univariable analysis of
OS showed that age group (HR= 2.90, 95% CI: 1.12–7.49,
p= 0.028), AJCC stage (HR= 4.56, 95% CI: 1.02–20.35, p=
0.046), and N stage (HR= 3.05, 95% CI: 1.07–8.74, p= 0.038)
predicted OS (Table 4; Figs. 2, 3 and 4).
Discussion
Our study found that patients with anal SCC were gen-
erally diagnosed at late stages. The most common
Table 2 Characteristics of patients, tumour and treatment modalities by gendera (Continued)
Variable All patient (N = 144)
n (%)
Females (N = 109)
n (%)
Males (N = 35)
n (%)
Yes 101 (70.1%) 78 (71.6%) 23 (65.7%)
No 36 (25.0%) 25 (22.9%) 11 (31.4%)
Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
Chemoradiotherapy
Yes 97 (67.4%) 76 (69.7%) 21 (60.0%)
No 40 (27.8%) 27 (24.8%) 13 (37.1%)
Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
Surgical operationb
Yes 57 (39.6%) 44 (40.4%) 13 (37.1%)
No 80 (55.6%) 59 (54.1%) 21 (60.0%)
Unknown 7 (4.9%) 6 (5.5%) 1 (2.9%)
a: IQR interquartile range; AJCC American Joint Committee on Cancer; SCC squamous cell carcinomas; CRT Chemoradiotherapy
b: Surgical operation did not include surgical biopsy for diagnosis
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symptoms in patients with anal SCC were bleeding, no-
ticing a lump, and pain. Some patients did not receive
standard treatment. T stage was a significant prognostic
factor of RFS, and age, AJCC stage, and N stage were
significant prognostic factors of OS.
Anal SCC is an uncommon malignancy [7]. Although
the incidence rate has been increasing in recent years, it is
still difficult to describe the epidemiological characteristics
of anal SCC due to its rarity. To our knowledge, our study
is by far the largest study in China to describe the clinical
and epidemiological characteristics and explore the prog-
nostic factors of outcomes of anal SCC patients. Another
study included only 21 anal SCC patients with much more
anal adenocarcinomas patients [6].
The smoking rate of different genders in the current
study was consistent with the smoking rate among entire
Table 3 Cox univariable analysis for recurrence-free survival
(RFS) according to patient, tumour and treatment modalities
characteristicsa
Univariable
Variable HR (95%CI) p
Age (years) (> 50 VS. ≤50) 0.96 (0.43–2.12) 0.918
Gender (Male VS. Female) 1.29 (0.48–3.43) 0.613
AJCC stage (III or IV VS. I or II) 46.17 (0.44–4836.63) 0.106
T stage (T3 or T4 VS. T1 or T2) 3.03 (1.10–8.37) 0.032
N stage (N1-N3 VS. N0) 0.86 (0.35–2.08) 0.730
Tumor size (> 20 mm VS. ≤20mm) 0.97 (0.33–2.85) 0.960
History of smoking (Yes VS. No) 0.56 (0.13–2.37) 0.431
Chemotherapy (Yes VS. No) 0.62 (0.27–1.41) 0.250
Radiotherapy (Yes VS. No) 0.95 (0.41–2.21) 0.897
CRT (Yes VS. No) 0.75 (0.33–1.68) 0.481
a: AJCC American Joint Committee on Cancer; HR Hazard ratio; CI Confidence
interval; CRT Chemoradiotherapy
Fig. 1 Recurrence-free survival according to T stage
Table 4 Cox univariable analysis for overall survival (OS)
according to patient, tumour and treatment modalities
characteristicsa
Univariable
Variable HR (95%CI) p
Age (years) (> 50 VS. ≤50) 2.90 (1.12–7.49) 0.028
Gender (Male VS. Female) 0.83 (0.33–2.13) 0.702
AJCC stage (III or IV VS. I or II) 4.56 (1.02–20.35) 0.046
T stage (T3 or T4 VS. T1 or T2) 2.33 (0.82–6.63) 0.113
N stage (N1-N3 VS. N0) 3.05 (1.07–8.74) 0.038
Tumor size (> 20 mm VS. ≤20mm) 0.63 (0.24–1.65) 0.343
History of smoking (Yes VS. No) 1.13 (0.33–3.83) 0.848
Chemotherapy (Yes VS. No) 1.26 (0.46–3.46) 0.652
Radiotherapy (Yes VS. No) 0.81 (0.33–1.96) 0.634
Chemoradiotherapy (Yes VS. No) 0.74 (0.31–1.76) 0.488
a: AJCC American Joint Committee on Cancer; HR Hazard ratio; CI Confidence
interval; CRT Chemoradiotherapy
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Fig. 2 Overall survival according to age group
Fig. 3 Overall survival according to American Joint Committee on Cancer (AJCC) stage
Lu et al. BMC Cancer          (2020) 20:679 Page 8 of 13
Chinese adults. In the current study, 130 patients had
the records of history of smoking. Among these 130 pa-
tients, approximate 13.1% of patients (45.2% of males
and 3.0% of females) had a history of smoking. The
smoking rate among males was much higher than that
among females. In 2010, Chinese Center for Disease
Control and Prevention carried out the Global Adult
Tobacco Survey (GATS) in China and reported that
smoking rate was 28.1% (52.9% of males and 2.4% of fe-
males) among Chinese adults [30]. The China Adult To-
bacco Survey (CATS) in 2015 found the smoking rate
was 27.7% among Chinese adults (52.1% of males and
2.7% of females), which did not change significantly from
the results reported in 2010 [31]. In the current study,
75.7% included patients were female, which resulted in
only 13.1% patients had a history of smoking.
Among 144 SCC patients, only a small proportion
were diagnosed at an early stage (10 [6.9%] at AJCC
stage I and 13 [9.0%] at T1 stage). This was similar to a
previous study of anal cancer (129 [71.7%] patients were
adenocarcinoma) in China that indicated only 7 of 126
(5.6%) patients were diagnosed at stage I [6]. However,
in the United States from 2003 to 2013, more than 30%
patients with anal SCC were diagnosed before stage II
[32]. The proportion of early diagnosis was significantly
higher than that of China. The symptoms reported in
our study were similar to those reported in previous
studies [6, 23], such as bleeding, pain, noticing a lump,
perianal itch, tenesmus, and altered bowel habit. The
median duration of symptoms was 90 days and in 39% of
patients, symptoms lasted longer than or equal to 180
days. This was presumably the reason why the median
tumour size was as large as 30 mm at diagnosis (and the
tumour of 34 (23.6%) patients were visible at diagnosis).
The long duration of symptoms until initial diagnosis
and the large tumour size at diagnosis both indicated
that patients were diagnosed too late. Together, these
findings suggest that anal SCC could be detected earlier
if individuals presented earlier to health care providers
[6, 23]. Further studies to improve the rate of early diag-
nosis of anal SCC should be conducted. Some measures
such as high resolution anoscopy (HRA), anal Papanicolau
(Pap) smears, and regular digital anorectal examination
(DARE) should be implemented in high-risk populations
to improve early diagnosis rate of anal SCC [33–38]. HRA
is identified as the gold standard for anal cancer screening
[34–36]. Anal Pap smears may increase the probability for
early diagnosis of anal lesions [37, 38]. An annual DARE
could help improve the diagnosis of anal abnormalities,
and in high risk population for anal SCC, such as MSM
living with HIV, routine implementation of DARE has
proven to be cost-effective [33, 39].
In our study we found that about two-thirds of pa-
tients received the standard treatment for anal SCC,
which was significantly higher than that reported in a
previous study carried out in 2011 by Peng et.al where
only 9.5% (2/21) received CRT. Peng et al. reported that
the reason so few received CRT was that doctors were
Fig. 4 Overall survival according to N stage
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not familiar with this method as a standard treatment of
anal SCC [6]. However, the results of our study also
showed issues including nonstandard treatment and mis-
diagnosis still existed. This pointed to the necessity of
education to raise awareness of this condition among
both patients and their health care providers, and the
importance of early diagnosis and treatment.
Clinical practice guidelines suggest that patients who
received the standard CRT could achieve a response rate
of 80–90%. The remaining 15% of patients whose re-
gional lesion do not respond to CRT can receive APR as
salvage treatment [3]. Among all 144 patients in our
study, 36 (25.0%) patients underwent APR initially. Fif-
teen (10.4%) patients were treated with local mass resec-
tion. Only two of them met the conditions for local
mass resection. Awareness of anal SCC symptoms and
treatment modalities should be further improved among
health care providers.
Anal SCC is strongly associated with HPV infection.
Recent study regarding cancer burden attributable to
HPV infection used 100% as the population-attributable
fraction of HPV in anal SCC, which meant that the au-
thors thought nearly all anal SCC were caused by HPV
infection [40]. And recent studies regarding the relation-
ship between anal SCC and HPV infection also reported
that HPV could be detected in more than 90% patients
with anal SCC [41–43]. However, only two patients in
our study were determined to be HPV positive. Most pa-
tients did not take HPV test, so the HPV infection status
were unclear for these patients. Until now, the rate of
HPV infection in anal SCC in China, which is of great
significance for the exploration of risk factors of anal
SCC, is still unknown. HPV test and HPV-related infor-
mation collection should be conducted among patients
with anal SCC in China. Previous studies also mentioned
that a prior HPV-related malignancy would increase the
risk of second cancer at sites related with HPV, espe-
cially among females [44–46]. That is to say, patients
with history of cervical, vaginal, vulvar cancers are more
likely to develop anal cancer. However, only two patients
had a history of cervical cancers, and another two pa-
tients had a history of vulvar cancer. Due to limitation of
current data, we could not explore the relationship be-
tween prior HPV-related malignancy and anal cancer,
which might be our future research direction.
In 2012, HPV 16/18 were responsible for 87.0% anal
cancer globally, and proportion rose to 95.9% for HPV
6/11/16/18/31/33/45/52/58 [47]. The HPV vaccines have
certain potential for the prevention of HPV-related anal
cancer. Between 2016 and 2018, bivalent HPV vaccine
targeting HPV types 16/18 and nonavalent HPV vaccine
targeting HPV types 6/11/16/18/31/33/45/52/58 have
been approved in mainland China [48]. However, only
right-age females can get HPV vaccine. In China in
2015, the age-standardized incidence rate (ASIR) of anal
cancer among males was higher than that among fe-
males (0.24 vs 0.17 per 100,000 person-years) [49].
Males, especially MSM, do not have routine access to
HPV immunization. Males also should be included in
HPV vaccination programs for prevention of HPV-
related cancers.
Four factors were identified as prognostic factors of
outcomes. In our current analysis, we found that ad-
vanced T stage at diagnosis was associated with shorter
RFS. Previous conducted in Norway reported that ad-
vanced T stage significantly increased the risk of recur-
rence [24]. Ghosn et al. reported that the status of the
margins and tumor size were important predictive fac-
tors of recurrence [50]. We also found that age, AJCC
stage, and N stage were identified as prognostic factors
of OS. Patients diagnosed at a later stage had poorer
prognosis which was consistent with the findings from
other studies [24, 50]. Elderly patients were more likely
have reduced OS, which was in line with the previous
study conducted in Norway [24].
Previous studies also mentioned that HPV infection
and its surrogate (i.e. p16) were strongly associated with
the outcome of anal SCC [51–54]. Compared with pa-
tients with HPV-positive/ p16-positive anal tumours, pa-
tients with HPV−/p16- tumours had significantly worse
outcome. HPV-negative/p16-negative was an independ-
ent predictor for reduced locoregional control, RFS and
OS [52, 53]. P53 expression was inversely correlated with
p16 expression, and p53 positive was an independent
prognostic factor for reduced relapse-free survival [53].
TP53 mutations occurred more frequently in HPV nega-
tive tumours, which not only was used to predict the
outcome of anal SCC, but also related to radiation ther-
apy resistance [52]. However, due to the limitation of
our data, we could not explore the relationship between
these biomarkers and outcome of anal SCC. Information
regarding these biomarkers should be collected in future
research.
Anal intercourse, a known risk factor for anal SCC, is
practiced in a significant proportion of heterosexual cou-
ples (6 to 40%) [55] and nearly all MSM couples. How-
ever, no patient in our study reported a history of
receptive anal intercourse or homosexual behaviors. This
may be a social desirability bias due to the fact that
homosexuality and anal intercourse are discriminated
against in China and people tend not to disclose their
sexual orientation and detailed sexual behaviors, espe-
cially for older people. Clinic data relevant to SCC
should include sexual behaviors and health care pro-
viders should actively collect this information. A large
proportion of patients with SCC were HIV-positive and
HIV status is associated with younger age at SCC diag-
nosis. Read et al. reported that nearly 20% (24/128) of
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patients with SCC in Australia were HIV-positive.
HIV-positive patients with SCC had smaller tumours
[23]. However, only one patient was recorded as being
HIV positive. In China nearly all HIV-positive pa-
tients are treated in designated infectious disease spe-
cialist hospitals. It is unlikely to have HIV-positive
SCC patients at cancer services. In the future, hospi-
tals treating HIV-positive people should be included
when collecting data for SCC patients. Exploring the
relationship between anal SCC and HIV status is an
interesting topic and may be the direction of our next
research. The gender ratio of male versus female in
our study was 1:3 while a study in Australia found
this ratio was 1:1. This may be because the majority
of HIV-positive SCC patients were not available at
cancer hospitals and a significant proportion of them
were MSM. The proportion of receptive anal inter-
course among Chinese females was much lower than
that among Australian females [56].
There were several limitations that need to be con-
sidered when interpreting the data. Our study was a
retrospective audit of clinical records. The rarity of
anal SCC and the lack of centralised reporting sys-
tem for anal SCC restricted our ability to find more
records which may lead to compromised representa-
tiveness of our sample. There is a lack of essential
SCC-relevant variables in the current clinical record-
ing system, including detailed sexual behaviors, HPV
testing result, HPV-related biomarkers, history of
other HPV-related cancers, and HIV status. The
tumor registration system in many medical institu-
tions did not systematically separate anal SCC from
adenocarcinoma, leading to underreported SCC pa-
tients. Meanwhile, the patients in our study were
mainly HIV-negative and female. Because of the re-
stricted population, the results of this study may not
be generalized. Our study also had several strengths.
Our study was the largest one on anal SCC in main-
land China. Another strength was the clinical re-
cords of patients were collected from 11 medical
institutions in various parts of China, which is more
representative compared with records obtained from
a single institution.
Conclusions
Our data illustrated that T stage of anal SCC was a
predictive factor of RFS, and age, AJCC stage, and N
stage were identified as prognostic factors of OS.
Among anal SCC patients, only a small fraction were
diagnosed at an early stage. The proportion of pa-
tients receiving CRT increased over the past decade.
However, the usage of CRT still needs to be im-
proved. Further research about identifying other pre-
dictive factors of outcomes e.g. biomarkers, improving
the rate of early diagnosis and improving the usage of
CRT should be conducted. More efforts are needed
to collect necessary information regarding HPV infec-
tion, biomarkers of HPV infection, history of HPV-
related cancer, and sexual behavioral from SCC
patients.
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